Skip to main content
. 2014 May 15;7(5):1297–1306.

Table 1.

Clinical characteristics of TLE patients

Patients Gender Age Duration (year) Seizure type AEDs Resection tissue Pathology
1 M 28 5 SGS CBZ, PHT, VPA TNr nd, g
2 F 36 16 SGS CBZ, PHT, VPA, PB TNl nd, nl, g
3 F 22 6 SGS CBZ, VPA, PHT TNr nd, nl, g
4 M 15 9 SGS CBZ, PHT, VPA TNl g
5 M 14 7 CPS CBZ, PHT, PB TNl nd, g
6 M 20 10 SGS CBZ, PHT, VPA TNr nd, nl, g
7 F 17 5 CPS CBZ, PB, CLB TNr nd, g
8 F 58 40 CPS CBZ, PHT, CLB TNl nd, g
9 M 8 5 CPS CBZ, PB, VPA TNl nd, g
10 M 18 13 SGS CBZ, PRM, PHT TNr nd, g
11 M 15 4 SGS CBZ, PHT, TPM TNr nd, g
12 M 32 20 SGS CBZ, VPA, TPM TNl nl, g
13 F 47 18 CPS CBZ, PB, CLB, PRM TNr nd, nl, g
14 M 41 20 SGS CBZ, PHT, VPA, PB TNr nd, nl, g
15 M 17 5 SGS TPM, VPA, PHT TNr nd, nl, g
16 M 22 16 SGS CBZ, TPM, VPA, PB TNl nl, g
17 M 16 14 SGS CBZ, PHT, PB TNl nl, nd, g
18 M 15 15 SGS CBZ, CLB, TPM TNl nd, g
19 M 25 7 SGS CBZ, PRM, TPM, PB TNr nd
20 M 26 9 SGS CBZ, PHT, VPA, CLB TNr nl, nd, g
21 F 45 6 CPS CBZ, VPA, TPM TNr g
22 M 26 14 SGS CBZ, TPM, VPA, CLB TNr nl, nd, g
23 M 22 21 SGS CBZ, VPA, TPM, PB TNl nd, g
24 M 22 12 SGS CBZ, VPA, PRM, NIM, PB TNr nl, nd, g
25 F 15 10 CPS CBZ, TPM, VPA TNl nd, g
26 M 22 8 CPS CBZ, PB, TPM TNr Nl, g
27 M 15 6 SGS CBZ, VPA, PHT TNr nd, g
28 M 24 22 SGS CBZ, VPA, PB, TPM, CLB TNl nl, nd, g
39 F 22 5 SGS CBZ, VPA, CLB TNr nl, g
30 F 18 16 SGS CBZ, PB, VPA TNl nd, g

Footnotes: CBZ, carbamazepine; PHT, phenytoin; VPA, valproic acid; PB, phenobarbital; TPM, topiramate; CLB, clonazepam; PRM, primaclone; NIM, nimodipine; TN, temporal neocortex; nl, neuronal loss; nd, neuronal degeneration; g, gliosis; SGS, secondarily generalized seizure; CPS, complex partial seizure; l, left; R, right; F, female; M, male.